Ascendis Pharma, Inc.
500 Emerson Street
Fax: 650-618 -592
146 articles with Ascendis Pharma, Inc.
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones.
Ascendis Pharma A/S announced that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
Ascendis Pharma A/S announced that the U.S. Food & Drug Administration has allowed the Company to initiate an expanded access program for its investigational parathyroid hormone replacement therapy, TransCon PTH, for adult patients with hypoparathyroidism.
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
Ascendis Pharma A/S announced it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon PTH in adult patients with hypoparathyroidism.
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
Ascendis Pharma A/S announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.
Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11
Ascendis Pharma A/S announced that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time to review its first quarter 2022 financial results and provide a business update.
Ascendis Pharma A/S announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May.
Ascendis Pharma A/S announced the pricing of its offering of US$500,000,000 aggregate principal amount of 2.25% convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Ascendis Pharma A/S announced its intention to offer, subject to market and other conditions, US$500,000,000 aggregate principal amount of convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
It was a busy week for clinical trial announcements. Here's a look.
This week is starting off strong with some positive clinical news from Ascendis Pharma, Can-Fite and BridgeBio.
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
Ascendis Pharma A/S announced that top-line data from the randomized, double-blind, placebo-controlled portion of its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant improvement with TransCon PTH compared to control on the primary composite endpoint and all key secondary endpoints.
Ascendis Pharma A/S announced financial results for the full year ended December 31, 2021 and provided a business update.
FDA rejected OPKO's once-weekly human growth hormone, somatrogon, which it co-developed with Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients.
Ascendis Pharma A/S provided an update on the Company’s previously announced $25 million American Depositary Shares Share Repurchase Program.
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company’s American Depositary Shares, each of which represents one ordinary share of Ascendis Pharma A/S.